20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)
Domenica Lorusso(Agostino Gemelli University Polyclinic), V. Makker(Memorial Sloan Kettering Cancer Center), Allison Martin Nguyen(Merck & Co., Inc., Rahway, NJ, USA (United States)), V.S. Prabhu(Merck & Co., Inc., Rahway, NJ, USA (United States)), N. Colombo(European Institute of Oncology), Rachid Massaad(MSD (Belgium)), A.D. Santin(Yale University), Mary McCormack(St Mary's Hospital), David S. Miller(Southwestern Medical Center), Q. Zhao(Eisai (United States)), Keiichi Fujiwara(Chiba University), Y.M. Kim(Asan Medical Center), Ronnie Shapira‐Frommer(Sheba Medical Center), Émeline Colomba(Université Paris-Saclay), Jodi A. McKenzie(Peter MacCallum Cancer Centre), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sally Baron‐Hay(Royal North Shore Hospital), Isabelle Laure Ray-Coquard(Université Claude Bernard Lyon 1), A. Casado Herráez(Hospital Clínico San Carlos)
Cited by 1
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|1.1k